2
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1676L |
C-Reactive Protein (CRP) 201-206 acetate
C-Reactive Protein (CRP) 201-206 acetate(130348-99-1 free base) |
Others | Others |
C-Reactive Protein (CRP) 201-206 acetate (C-Reactive Protein )(130348-99-1 free base) 是 C-反应蛋白的 201-206 片段。 C-反应蛋白 (CRP) 醋酸盐是炎症的原型标志物,是心血管风险标志物,可能促进动脉粥样硬化形成。 | |||
TP1676 |
C-Reactive Protein (CRP) (201-206)
C-Reactive Protein (CRP) 201-206 |
Others | Others |
C-Reactive Protein (CRP) (201-206) 是 C-反应蛋白的 201-206 片段。其中C-反应蛋白 (CRP) 是炎症的原型标志物,是心血管风险标志物,可能促进动脉粥样硬化形成。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |